Severity: 8192
Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated
Filename: helpers/my_audit_helper.php
Line Number: 8900
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
We study the problem of estimating the trace of a matrix that can only be accessed through matrix-vector multiplication. We introduce a new randomized algorithm, Hutch++, which computes a (1 ± ) approximation to tr( ) for any positive semidefinite (PSD) using just (1) matrix-vector products. This improves on the ubiquitous , which requires (1 ) matrix-vector products. Our approach is based on a simple technique for reducing the variance of Hutchinson's estimator using a low-rank approximation step, and is easy to implement and analyze. Moreover, we prove that, up to a logarithmic factor, the complexity of Hutch++ is optimal amongst all matrix-vector query algorithms, even when queries can be chosen adaptively. We show that it significantly outperforms Hutchinson's method in experiments. While our theory requires to be positive semidefinite, empirical gains extend to applications involving non-PSD matrices, such as triangle estimation in networks.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553228 | PMC |
http://dx.doi.org/10.1137/1.9781611976496.16 | DOI Listing |
J Neurooncol
January 2025
Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.
Cancers (Basel)
August 2024
Department of Radiation Oncology, University of Washington and Radiation Oncology Division, Fred Hutch Cancer Center, Seattle, WA 98195, USA.
Because proton beam therapy (PBT) can lower the dose of radiation to the heart, lungs, and breast, it is an established radiation modality for patients with Hodgkin lymphoma (HL). Pencil beam scanning (PBS) PBT facilitates the treatment of more extensive targets. This may be especially of value for lymphoma patients who require RT to both mediastinal and axillary targets, defined here as extended target RT (ETRT), given the target distribution and need to minimize the lung, heart, and breast dose.
View Article and Find Full Text PDFNeurocrit Care
August 2024
Department of Neurology, Northwestern Medicine, Chicago, IL, USA.
Background: The objective of this study was to define clinically meaningful phenotypes of intracerebral hemorrhage (ICH) using machine learning.
Methods: We used patient data from two US medical centers and the Antihypertensive Treatment of Acute Cerebral Hemorrhage-II clinical trial. We used k-prototypes to partition patient admission data.
J Immunother Cancer
May 2024
Cellular Immunotherapy Program, Krantz Family Center for Cancer Research, Massachusetts General Hosptial, Charlestown, Massachusetts, USA
Background: Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved CAR-T cell products use the FMC63-based αCD19 single-chain variable fragment, derived from a murine monoclonal antibody, as the extracellular binding domain. Clinical studies demonstrate that patients develop humoral and cellular immune responses to the non-self CAR components of autologous CAR-T cells or donor-specific antigens of allogeneic CAR-T cells, which is thought to potentially limit CAR-T cell persistence and the success of repeated dosing.
View Article and Find Full Text PDFNature
May 2024
Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs and revealed how quickly viral escape can curtail effective options. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab. Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination and is challenging to replace with existing approaches.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!